| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania 19107
The fragile histidine triad (FHIT) gene at chromosome 3p14.2 is a tumor suppressorgene that is altered mainly by deletion in a large fraction of human tumors, including breast cancers. To evaluate the potential of FHIT gene therapy in this type of cancer, we have studied the biological effects of adenoviral FHIT transduction (Ad-FHIT) in breast cancer cell lines. The results showed that, after FHIT restoration in BT-549, MDA-MB-436, and HCC1806 cells, they underwent apoptosis by activation of the intrinsic pathway. In all three cell lines infected with Ad-FHIT, we have found activation of caspase-2, which is required for permeabilization of mitochondria, release of cytochrome c, and apoptosis. Furthermore, Fhit overexpression produces alteration in cell cycling properties, as well as reduction of the tumorigenic potential in nude mice.
This article has been cited by other articles:
|
|
 |
|
  S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Semba, S.-Y. Han, H. R. Qin, K. A. McCorkell, D. Iliopoulos, Y. Pekarsky, T. Druck, F. Trapasso, C. M. Croce, and K. Huebner Biological Functions of Mammalian Nit1, the Counterpart of the Invertebrate NitFhit Rosetta Stone Protein, a Possible Tumor Suppressor J. Biol. Chem., September 22, 2006; 281(38): 28244 - 28253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Semba and K. Huebner Protein Expression Profiling Identifies Cyclophilin A as a Molecular Target in Fhit-Mediated Tumor Suppression Mol. Cancer Res., August 1, 2006; 4(8): 529 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pichiorri, F. Trapasso, T. Palumbo, R. I. Aqeilan, A. Drusco, B. W. Blaser, D. Iliopoulos, M. A. Caligiuri, K. Huebner, and C. M. Croce Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35. Clin. Cancer Res., June 1, 2006; 12(11): 3494 - 3501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kim, J. W. Kim, J. Han, Y. M. Shim, J. Park, and D.-H. Kim Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer. Cancer Res., April 15, 2006; 66(8): 4049 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Weiske and O. Huber The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-{beta}-catenin-mediated transcription J. Cell Sci., July 15, 2005; 118(14): 3117 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vecchione, C. Sevignani, E. Giarnieri, N. Zanesi, H. Ishii, R. Cesari, L. Y. Y. Fong, L. G. Gomella, C. M. Croce, and R. Baffa Inactivation of the FHIT Gene Favors Bladder Cancer Development Clin. Cancer Res., November 15, 2004; 10(22): 7607 - 7612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kim, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung Carcinogenesis, November 1, 2004; 25(11): 2165 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schweizer, C. Briand, and M. G. Grutter Crystal Structure of Caspase-2, Apical Initiator of the Intrinsic Apoptotic Pathway J. Biol. Chem., October 24, 2003; 278(43): 42441 - 42447. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
